Information Provided By:
Fly News Breaks for April 16, 2018
INCY, NLNK
Apr 16, 2018 | 07:24 EDT
Cantor Fitzgerald analyst Mara Goldstein reiterates a Neutral rating on NewLink Genetics (NLNK) with a $7 price target after the company over the weekend presented data from a Phase I study of indoximod in diffuse intrinsic pontine glioma. While positive, the data are unlikely to "sway investors at this point" given the recent failure of Incyte's (INCY) epacadostat, Goldstein tells investors in a research note.
News For NLNK;INCY From the Last 2 Days
INCY
INCY
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.